Johnson & Johnson: Data From Esketamine Nasal Spray Phase 3 Studies Showed Rapid Reduction of Depressive Symptoms in Adult Patients
September 09, 2019
September 09, 2019
TITUSVILLE, New Jersey, Sept. 9 -- Janssen Pharmaceutical Companies, a subsidiary of Johnson and Johnson, issued the following news release:
* * *
- Global Clinical Program Is The First to Study This Severely Ill Patient Population, Who Are Typically Excluded From Antidepressant Treatment Studies
* * *
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive results from two pivotal Phase 3 clinical studies (ASPIRE . . .
* * *
- Global Clinical Program Is The First to Study This Severely Ill Patient Population, Who Are Typically Excluded From Antidepressant Treatment Studies
* * *
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive results from two pivotal Phase 3 clinical studies (ASPIRE . . .